ACTRN12609000213246已完成1 期
A Dose-Escalation, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701 in Iron-Overloaded Male Patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- Male
入选标准
- •Trasnfusion-dependent patients wo have transfusional overload, requiring chronic treatment with deferoxamine, deferasirox or deferiprone. Patients must be willing to discontinue all existing iron chelation therapies for a minimum of seven days prior to admission to clinic.
排除标准
- •Received or is anticipated to receive a new prescription systemic or topical medication within 14 days of study start, or over-the-counter medications within 48 hours. Any condition that would interfere with drug absorption (ie chronic diarrhoea).
研究者
相似试验
已完成
1 期
Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46Cutaneous, subcutaneous, head and neck*, or nodal tumours*except for pharyngeal, laryngeal and tongue base tumours and those tumours in the anterior neck (from posterior border of sternocleidomastoid on each side)Cutaneous, subcutaneous, head and neck*, or nodal tumours*except for pharyngeal, laryngeal and tongue base tumours and those tumours in the anterior neck (from posterior border of sternocleidomastoid on each side)Cancer - Head and neckCancer - Malignant melanomaCancer - Non melanoma skin cancerACTRN12614000685617QBiotics Limited22
已完成
1 期
A study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumorsSolid tumorsCancer - Any cancerACTRN12616000228482Accendatech AU Pty Ltd36
招募中
1 期
A study to evaluate the safety,tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumorsACTRN12618001934235Accendatech AU Pty Ltd40
招募中
1 期
A study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).Glioblastoma MultiformeACTRN12621001172897Accendatech AU Pty Ltd21
已完成
1 期
A phase 1 study of dendrimer-docetaxel (DEP(TM) Docetaxel) in patients with advanced cancer.CancerACTRN12614000171617Starpharma Pty Ltd30